The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: Olink
  • Initiator Type: Government
  • Disease focus:
    Irritable Bowel Disease
  • Location: Europe


The Inflammatory Bowel Disease CHARACTERization by a multi-modal integrated biomarker study (IBD-Character) Consortium is a collaborative effort to advance understanding of the inflammatory bowel diseases ulcerative colitis and Crohn’s disease and to increase diagnostic precision in detection of the diseases in their early manifestation.


The consortium will generate the largest collection of samples so far assembled from treatment naïve patients recently diagnosed with inflammatory bowel disease (IBD). Deoxyribonucleic acid (DNA) methylation and ribonucleic acid (RNA) transcription status, protein markers, gut microbial content, patient genotype for known susceptibility loci, and classical clinical data will be extensively analyzed for the characterization of the cohort in order to create a molecular snapshot of IBD in its early manifestation. This massive molecular profiling will be used to yield a list of biomarkers indicative for onset of the disease.

The participating small and medium-sized enterprises (SMEs) will develop assays capable of analyzing panels of several hundred relevant protein markers as well as methods for rapid profiling of gut microbial content relevant for IBD. The proposed biomarkers will form a solid ground for development of improved diagnostic assays and will be a rich source to mine for novel therapeutic targets.

Based on the findings within the consortium, results are expected to improve many aspects of patient care, including the development of new personalized medical strategies and treatments.

Consortium History

IBD-Character is a four-year project running from Dec. 1, 2012, until Nov. 30, 2016.


IBD-Character was started with a €6 million grant from the European Commission´s Seventh Framework Program.


Points of Contact

Jack Satsangi (Coordinator) UK
The University of Edinburgh,

Sponsors & Partners

Centro Nacional de Analisis Genomico

Diagenode (SME)

Genetic Analysis (SME)

Instituto Aragones de Ciencias de la Salud/IIS Aragon

Karolinska Institutet

Linkopings Universitet

Olink Bioscience (SME)

Orebro University Hospital

The University of Edinburgh

Universitetet I Oslo

Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.